COVID-19 vaccine — and this time, it’s designed to tackle one of the COVID-19 variants.The study, which involves 2,250 participants across four different countries, aims to build immunity against a variant of concern known as the Beta variant, which first emerged in South Africa.
Researchers also said they’ll use the study to better understand COVID-19 and its associated issues.“Testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the pandemic coronavirus, should their use be needed,” said Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group, in a press release.